Namaxir (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, including immune cells and cancer cells, and also reduces inflammatory cytokine production, providing both antineoplastic and immunosuppressive effects.

The specific dose of Namaxir is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Dosage regimens vary widely across indications and must be individualized by a qualified healthcare professional.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate is a folate antagonist, distinct from biologic agents such as TNF‑α inhibitors. It is generally less expensive, can be administered via injection, and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis. However, biologics may be preferred when patients do not respond adequately to methotrexate or have contraindications.

Namaxir should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product. If temporary storage at room temperature is unavoidable, keep the duration short and avoid exposure to heat.

Namaxir is supplied for parenteral use and can be given by epidural, intra‑articular or intramuscular injection, depending on the clinical indication. Administration technique and site are determined by the treating physician and should follow aseptic procedures.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute kidney injury, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, renal function, blood counts, and respiratory symptoms.

Namaxir is contraindicated in pregnant or breastfeeding women, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, and individuals receiving live vaccines. Caution is also advised for patients with pre‑existing blood disorders or uncontrolled infections.